Merck (MRK) Tops Q2 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. LITE
5. CL
6. LYB
7. TFII
8. SPY
9. AAPL
10. NVT

Go back to Merck (MRK) Tops Q2 EPS by 14c

Merck to Collaborate with Generex to Evaluate KEYTRUDA (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer

July 31, 2017 9:41 AM EDT

Merck (NYSE: MRK) (known as MSD outside the United States and Canada), through a wholly-owned subsidiary today announced that through a collaboration agreement with Generex Biotechnology Corporation and its wholly-owned subsidiary, Antigen Express, Inc has entered into a clinical trial to evaluate Antigens AE37 cancer vaccine in combination with Mercks anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.

The combination of AE37 plus KEYTRUDA follows previous studies, in which both... More